<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03486340</url>
  </required_header>
  <id_info>
    <org_study_id>CATCH2018</org_study_id>
    <nct_id>NCT03486340</nct_id>
  </id_info>
  <brief_title>Prevention of Chest Pain in Chemo-treated Cancer Patients</brief_title>
  <acronym>CATCH</acronym>
  <official_title>Prevention of CArdioToxic-related CHest Pain in Cancer Patients Treated With 5-fluorouracil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Region of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vejle Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, exploratory, randomised clinical trial. Patients with diagnosed cancer
      that are to be treated with 5-fluorouracil (5-FU) will be randomised into standard
      oncological treatment or a cardiological assessment prior to the 5-FU treatment. The
      investigators hypothesize that aggressive management of ischemic risk factors in asymptomatic
      patients will reduce the number of hospitalisations and investigations for acute coronary
      syndrome during and after 5-FU treatment and that patients with high coronary artery calcium
      scores are more likely to experience chest pain during the treatment with 5-FU.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute coronary syndrome</measure>
    <time_frame>6 months</time_frame>
    <description>Composite endpoint of the incidence of overall mortality, chest pain requiring hospital admittance, the incidence of coronary angiography intervention and acute coronary syndrome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chest pain</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of chest pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Solid Carcinoma</condition>
  <condition>5-Fluorouracil Toxicity</condition>
  <condition>Cardiotoxicity</condition>
  <condition>Chemotherapeutic Toxicity</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Coronary Artery Calcification</condition>
  <condition>Chest Pain</condition>
  <arm_group>
    <arm_group_label>Cardiological assessment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a sub-acute cardiologic assessment and aggressive management of risk factors before oncologic treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard chemotherapeutic treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiologic assessment</intervention_name>
    <description>Aggressive ischemic risk factor management</description>
    <arm_group_label>Cardiological assessment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically verified cancer

          -  First-time treatment with 5-FU/Capecitabine

          -  Expected remaining lifetime &gt; 6 months

          -  Informed consent

        Exclusion Criteria:

          -  Known ischemic heart disease

          -  Ischemia-suspicious symptoms prior to 5-FU treatment

          -  Ischemia-suspicious ECG-changes prior to 5-FU treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vibeke B Hansen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vejle Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars H Jensen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology, Vejle Hospital, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mads D Lyhne, MD</last_name>
    <phone>+45 20450486</phone>
    <email>Mads.Dam.Lyhne@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vibeke B Hansen, MD, PhD</last_name>
    <email>vibeke.brogaard.hansen@rsyd.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Departments of Oncology and Medicine, Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2018</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Chest Pain</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

